Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Complement C5 inhibitor treatment with ravulizumab or eculizumab for paroxysmal nocturnal hemoglobinuria (PNH) improves outcomes and survival. Some patients remain anemic due to clinically significant extravascular hemolysis (cs-EVH: hemoglobin [Hgb] ≤9.5 g/dL and absolute reticulocyte count [ARC] ≥120×109/L).
View Article and Find Full Text PDF[Prognostic factors of immunosuppression therapy combined with eltrombopag in the treatment of childhood severe aplastic anemia].
Zhonghua Er Ke Za Zhi
December 2024
Department of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics (Capital Medical University),Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing100045, China.
To analyze the influence factors on the efficacy of immunosuppression therapy (IST) combined with eltrombopag and IST alone in the treatment of childhood severe aplastic anemia (SAA). A retrospective cohort study. A total of 124 children with SAA who were initially treated with IST at Beijing Children's Hospital from March 2017 to May 2020 were enrolled.
View Article and Find Full Text PDFSafety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia.
Blood
November 2024
Mayo Clinic, Rochester, Minnesota, United States.
Article Synopsis
- This study tested pegcetacoplan, a targeted therapy aimed at treating these conditions, over 48 weeks in two patient groups with CAD and wAIHA who received either 270 or 360 mg/day.
- Results showed that pegcetacoplan was generally well tolerated with minimal serious side effects, and it effectively increased hemoglobin levels and reduced hemolysis in both groups.
Assessment of myeloid response and iron status among Sudanese pediatric ESKD on hemodialysis through reticulocyte parameters and β-globin mRNA expression.
BMC Nephrol
October 2024
Department of Pathology, Faculty of Medicine and Health Sciences, Omdurman Islamic University, Khartoum, Sudan.
Background: Sudanese children with End-Stage Kidney Disease (ESKD) often show limited improvement in hemoglobin levels despite treatment with recombinant human erythropoietin (rHuEPO). This study aims to assess the response to rHuEPO therapy by analyzing β-globin mRNA expression and reticulocyte parameters. Additionally, it classifies anemia among Sudanese pediatric patients based on iron status, considering age and gender as biological markers for evaluating treatment response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!